Faeth Therapeutics outlines PIKTOR PI3K-alpha/mTOR inhibitor regimen in corporate presentation
FTH•Market opportunity framing
The company framed market opportunities at about $15-20 billion in breast cancer and about $2-3 billion in endometrial cancer.
PIKTOR regimen and trial timeline
Faeth Therapeutics outlined its oral PI3K/AKT/mTOR regimen PIKTOR, combining serabelisib with sapanisertib for multi-node pathway blockade.
Phase 2 endometrial topline data are targeted by year-end 2026; interim Phase 1b/2 breast data are expected in 2H 2027.
The endometrial Phase 2 PIK-201 study is a single-arm trial of about 40 patients, enrolling post-ICI and carboplatin patients with PAM-pathway mutations.
A prior Phase 1b endometrial subgroup showed 80% ORR, including 3 complete responses, with median PFS of 11 months.
